Skip to main content

Juvaris to Use Antigen Discovery's Protein Microarray Screening System

NEW YORK (GenomeWeb News) – Juvaris BioTherapeutics will use Antigen Discovery's high-throughput protein microarray screening system to discover disease-specific antigens for use in vaccines, Juvaris said today.

Antigen Discovery will retain rights to diagnostics related to the antigens.

Burlingame, Calif.-based Juvaris said that it will sponsor research for multiple disease targets and pay Antigen Discovery upfront payments. Juvaris will select optimal antigens from Antigen Discovery's efforts to combine with its own adjuvant technology to create highly immunogenic prophylactic and therapeutic vaccines against major unmet medical needs, it said.

Further terms of the alliance were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.